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Context. If access to effective palliative care is to extend beyond cancer patients,
an understanding of the comparative prevalence of palliative care problems
among cancer and non-cancer patients is necessary.
Objectives. This systematic review aimed to describe and compare the
prevalence of seventeen palliative care-related problems across the four palliative
care domains among adults with advanced cancer, acquired immune deficiency
syndrome, chronic heart failure, end-stage renal disease (ESRD), chronic
obstructive pulmonary disease, multiple sclerosis, motor neuron disease,
Parkinson’s disease, and dementia.
Methods. Three databases were searched using three groups of keywords. The
results of the extraction of the prevalence figures were summarized.
Results. The electronic searches yielded 4697 hits after the removal of 1784
duplicates. Of these hits, 143 met the review criteria. The greatest number of
studies were found for advanced cancer (n¼ 57) and ESRD patients (n¼ 47),
and 75 of the 143 studies used validated scales. Few data were available for
people living with multiple sclerosis (n¼ 2) and motor neuron disease (n¼ 3).
The problems with a prevalence of 50% or more found across most of the
nine studied diagnostic groups were: pain, fatigue, anorexia, dyspnea, and
worry.
Conclusion. There are commonalities in the prevalence of problems across
cancer and non-cancer patients, highlighting the need for palliative care to be
provided irrespective of diagnosis. The methodological heterogeneity across the
studies and the lack of non-cancer studies need to be addressed in future
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The number of deaths from chronic rather
than acute diseases is expected to increase
worldwide.1e3 A consequence of the aging pop-
ulation is that the time before death is differen-
tiated by longer dying trajectories, with a higher
prevalence of symptoms, resulting in longer
and varied care needs at the end of life.4 To
effectively anticipate patients’ needs, and plan
palliative care services for non-cancer patients,
we must understand how prevalent palliative
careerelated problems are across different
diagnostic groups.5,6 Although individual
studies have considered this, only the Solano
et al7 review in 2006 attempted to bring data
together across studies. However, only five con-
ditions were appraised, and a considerable
amount of data have been published since
then. In addition, the review of Solano et al7 re-
view focused on physical and psychological
symptoms, rather than wider palliative caree
related problems. Therefore, this systematic re-
view aimed to compare the prevalence of 17
palliative careerelated problems within the
four World Health Organization (WHO) pallia-
tive care domains (the physical, psychological,
social, and spiritual domains)8 among adults
with advanced stage cancer, acquired immune
deficiency syndrome (AIDS), chronic heart fail-
ure (CHF), end-stage renal disease (ESRD),
chronic obstructive pulmonary disease
(COPD), multiple sclerosis (MS), motor
neuron disease (MND), Parkinson’s disease,
and dementia. We chose to include people
living with MS, MND, Parkinson’s disease, and
dementia in our search because these neurode-
generative diseases show a different disease tra-
jectory in comparison with the other diseases.9
People living with dementia were included
because of the increasing aging population.10
Two main objectives were set: 1) to describe
and compare the prevalence of palliative
careerelated problems among advanced can-
cer and these eight advanced non-cancer diag-
nostic groups of patients, and 2) to describe
and compare the characteristics of the preva-
lence studies.Methods
Study Design
This systematic review was conducted in line
with the PRISMA 2009 checklist, the PRISMA
Flow Diagram, and the Center for Reviews
and Dissemination procedures.11,12 We used
the Assessment of Multiple SysTemAtic Re-
views (AMSTAR) measurement tool to ensure
the methodological quality of our review.13
The AMSTAR uses 11 questions each of which
needs to be answered using the following pos-
sibilities: yes, no, cannot answer, or not appli-
cable. To have the highest quality ranking, all
applicable questions should be answered with
‘‘yes.’’ K. M. conducted the search and the initial
screening; R. H. reviewed any articles where
there was a question as to whether they met
study criteria. I. J. H. adjudicated. The reference
lists within the full texts also were searched.
Search Strategy
We searched three electronic medical data-
bases, namely Medline (1966 to February
2013), Embase (1988 to February 2013), and
PsycINFO (1985 to February 2013), using
three groups of keywords. Within each group
of keywords, the words were combined using
OR. The three groups of keywords were then
combined using AND.
Keyword Group 1: worry; depression, low
mood, sadness, mood; anxiety, adjustment dis-
orders (psychological palliative care domain);
wellbeing; peace; spiritual wellbeing; meaning
of life; religion; spirituality (spiritual palliative
care domain); support; information; family
(social palliative care domain); pain; confu-
sion, delirium, cognitive failure; breathless-
ness, dyspnoea, dyspnea; fatigue, weakness;
insomnia, poor sleeping; anorexia; nausea;
diarrhea, diarrhea; constipation (physical palli-
ative care domain); symptoms. These words
were selected as the most appropriate words
to investigate the 17 palliative careerelated
problems. Because different terms are used
to define problems, we used more than one
keyword for the following problems: poor
sleeping for insomnia; weakness for fatigue;
662 Vol. 48 No. 4 October 2014Moens et al.low mood, mood and sadness for depression;
dyspnoea or dyspnea for breathlessness; and
delirium and cognitive failure for confusion.
Keyword Group 2: dying, end of life, termi-
nally ill, hospice$, palliative care, terminal
care, advanced, terminal disease$. These words
were selected to capture samples of patients in
advanced disease stage.
Keyword Group 3: terminal disease$, advanced
cancer$, metastatic cancer$, AIDS, end stage
heart disease$, end stage heart failure, end
stage respiratory disease$, end stage chronic
obstructive pulmonary disease$, end stage
COPD, end stage renal disease$, end stage
renal failure, MS, MND, Parkinson disease$,
dementia. These words were selected to iden-
tify the specified diagnostic groups.
These keywords were derived from those
that were successfully used in the reviews ofFig. 1. Inclusion and exclusion criteria of search. AIDS¼ acq
ease; COPD¼ chronic obstructive pulmonary disease; ESRD
MND¼motor neuron disease.Solano et al7 and Simms et al.14 Simms
et al14 used the WHO definition of palliative
care8 to extract keywords identifying each
palliative care domain. We refined our key-
words using the synonyms for problems
reported in the literature on symptom guid-
ance and systematic reviews in palliative care.15
Inclusion/Exclusion Criteria
Fig. 1 presents the inclusion and exclusion
criteria that were applied in the literature
search.
Data Extraction
The data from each study were extracted to
a common table with predesigned headings,
namely reference, year of publication, country
of origin; sample description; study design
(measurement methods/tools, point or perioduired immune deficiency syndrome; HD¼ heart dis-
¼ end-stage renal disease; MS¼multiple sclerosis;
Vol. 48 No. 4 October 2014 663Prevalence of Palliative Care Problemsprevalence); and findings (% prevalence of
problems per palliative care domain).
Describing and Comparing the Studies’
Characteristics
The characteristics of all the studies are
described in Table 1, which presents the total
number of studies retained, total combined
sample size, the nature of the prevalence
measured (period/point), the period preva-
lence time ranges (minimum-maximum), the
countries in which the studies were conducted,
and the measurement methods used.
Data Analysis: Describing and Comparing the
Prevalence of Problems
The results of the extraction of the preva-
lence figures of all included studies are sum-
marized using minimum and maximum
percentage ranges, and the problems are cate-
gorized by palliative care domain in line with
the WHO definition8 (Table 2). Meta-analytic
techniques were not appropriate to analyze
the prevalence data because of the heteroge-
neity between studies in terms of measurement
tools and study designs. Nevertheless, we re-
viewed and present the number of studies
that showed the prevalence of a problem in a
particular diagnostic group of 50% or more.Results
Retrieval Data
The electronic searches of the three data-
bases yielded 4697 hits after removal of 1784
duplicates. A total of 143 studies1,5,16e156 met
the inclusion/exclusion criteria for the synthe-
sis. The PRISMA flow diagram reports the
search strategy and the results yielded (Fig. 2).
The assessment of the methodological qual-
ity of our systematic review using the AMSTAR
measurement tool indicated that 10 of the 11
questions could be answered positively, that
is, that the following actions are executed
and reported in the review: an a priori design
is provided, a duplicate study selection and
data extraction are executed, a comprehensive
literature search is performed, the status of
publication is used as an inclusion criterion, a
list of studies that were included and excluded
is provided, the characteristics of the included
studies are provided, the scientific quality of
the included studies is used to formulateconclusions, the method used to combine the
findings of the studies is appropriate, and the
conflict of interest is stated at the end of this
article. The 11th item or question of the
AMSTAR reviews if the likelihood of publica-
tion bias is assessed. This was not applicable
for our study as we could not use statistical tests
to analyze our results because of the heteroge-
neity across all included studies.
Characteristics of Included Studies
The greatest number of studies by diag-
nostic group were found for advanced cancer
(n¼ 57) and ESRD patients (n¼ 47; Table 1).
The lowest number of studies were found for
MND (n¼ 3) and MS patients (n¼ 2). The
greatest number of studies originated from
the U.S. (n¼ 57), the U.K. (n¼ 20), and Can-
ada (n¼ 13). In the advanced cancer diagnostic
group, 37 of the 57 studies used a point preva-
lence to collect data, and in the ESRD patient
disease group, 28 of the 47 studies used a
period prevalence with a minimum-maximum
time range of ‘‘past two days’’ to ‘‘the last two
months.’’ For all the other diagnostic groups,
a period prevalence was primarily used. Consid-
ering the measurement tools used across the
advanced cancer and non-cancer diagnostic
groups, 75 of the 143 studies used validated
scales. For data collection among patients with
advanced dementia, four of the seven studies
used chart reviews.
Describing and Comparing Prevalence Data
The prevalence figures reported in the 143
studies are summarized using minimum and
maximum prevalence ranges (Table 2). In
this table, the different terms used for each
palliative careerelated problem across all the
studies are presented to highlight the varying
definitions. For example, we found studies
investigating ‘‘shortness of breath’’ or ‘‘respira-
tory distress’’ to indicate the study of dyspnea
or breathlessness.
Among people living with MND and MS,
there were many problems for which we did
not find prevalence data, for example,
anorexia, delirium, diarrhea, and worry, as
well as for all the spiritual and social palliative
careerelated problems. For certain diseases,
we only found one study on the prevalence of
a problem (e.g., fatigue in people living with de-
mentia, Parkinson’s disease, and MS; Table 2).
Table 1
Characteristics of Included Prevalence Studies (N¼ 143)
Characteristics Cancer COPD CHF ESRD Dementia AIDS Parkinson MND MS
Total number of
studies
57 10 8 47 7 8 9 3 2
Total sample
(patients), all
studies
34,866 2045 1310 11,140 868 1864 25,941 221 214
Total number of
point
prevalence
studiesa
37, of which two
studies
presented both
a point and a
period
prevalence
1 1 11, of which one
study presented
both a point and
a period
prevalence
2 d d d d
Total number of
period
prevalence
studies
17, of which two
studies
presented both
a point and a
period
prevalence
8 7, of which one
study presented
both a point and
a period
prevalence
28, of which one
study presented
both a point and
a period
prevalence
d 5 6 1 1
Period prevalence
time ranges
(minimum-
maximum)
Three Days-past
week
Last three days-
final year of life
Last year of life Past two days-last
two months
d Last two days-last
two weeks
Past two weeks-last
month
Last month
of life
Last three
days
Total number of
studies of which
the point or
period of
prevalence was
not specified
7 1 1 10 5 3 3 2 1
Total number of studies conducted in the following countries
The
Netherlands,
n¼ 6
3 1 1 1
Germany, n¼ 5 4 1
Austria, n¼ 1 1
France, n¼ 3 2 1
Italy, n¼ 7 5 1 1
Spain, n¼ 5 3 1 1
Switzerland,
n¼ 2
1 1
United
Kingdom,
n¼ 20
7 3 2 5 1 1 1
Ireland, n¼ 1 1
China, n¼ 6 4 2
Korea, n¼ 1 1
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Japan, n¼ 3 2 1
India, n¼ 1 1
Australia, n¼ 5 2 1 1 1
New Zealand,
n¼ 2
2
Canada, n¼ 13 2 1 10
Sweden, n¼ 3 1 1 1
Norway, n¼ 1 1
Denmark, n¼ 1 1
Romania, n¼ 1 1
Hungary, n¼ 1 1
South Africa,
n¼ 2
1 1
Israel, n¼ 3 2 1
Africa, n¼ 1 1
U.S., n¼ 57 16 4 3 18 3 6 6 1
Number of studies using the following symptom/problem measurement methods:
Validated
assessment
scales
24 7 2 29 1 4 5 1 2
Self-developed
items list or
checklist
22 2 4 13 1 2 2 1
Medical records
or patient
reports
10 2 5 4 2 1
Minimum data
set review
1 1
Method not
specified
1 1 1
COPD¼ chronic obstructive pulmonary disease; CHF¼ chronic heart failure; ESRD¼ end-stage renal disease; AIDS¼ acquired immune deficiency syndrome; MND¼motor neuron disease; MS¼multiple
sclerosis.
aPoint prevalence time points include measurements at the moment and those over the last 24 hours.
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Table 2
Prevalence Summary Grid Derived From 143 Studies
Domain
Problems and
Number of
Different
Studies
for Each
Problem
for All
Diagnostic
Groups (n)
Minimum-Maximum Prevalence % of Each Problem eferences
Total Sample of Patients (N ) for Each Probl
Total Number of Studies (n) for Each Probl
Number of Studies That Report Prevalence for a Problem $50% (n $50%)
Cancer COPD CHF ESRD Dementia AIDS Parkinson MND MS
Physical: Fatigue/
tiredness/
weakness
n¼ 58
23e100%5,17,18,
21,23e26,28,
31,34,37,
38,40,43,
45,47e50,
52e54,56e59,
64,65,67e71
N¼ 23,825
n¼ 34
n $50%¼ 25
32e96%1,74,
75,77,79,a
N¼ 500
n¼ 5
n $50%¼ 3
42e82%79,83,84
N¼ 212
n¼ 3
n $50%¼ 2
13e100%87,88,90,
91,93,100,101,
106,117,128,129
N¼ 1403
n¼ 11
n $50%¼ 7
22%137
N¼ 50
n¼ 1
43e9 141,143,
145
N¼ 5 8
n¼ 3
n $50 ¼ 2
42%149
N¼ 101
n¼ 1
- 80%156
N¼ 52
n¼ 1
Anorexia
n¼ 10
76e95%63,67,70
N¼ 1098
n¼ 3
64e67%1,a
N¼ 87
n¼ 1
- 38e64%95,103,
106,128
N¼ 788
n¼ 4
n $50%¼ 3
- 82%1
N¼ 5
n¼ 1
13%154
N¼ 123
n¼ 1
- -
Pain (including
different
origins)
n¼ 86
30e94%5,16e19,
21e25,27e29,31,
32,34,35,37e40,
42e52,54e60,
63e65,67e71
N¼ 29,966
n¼ 47
n $50%¼ 4
21e77%1,72e75,
77,79,a
N¼ 1730
n¼ 7
n $50%¼ 3
14e78%73,79,
81e85
N¼ 1230
n¼ 7
n $50%¼ 2
11e83%86e88,93,
94,100,101,
103,131,b
N¼ 814
n¼ 9
n $50%¼ 6
14e63%85,
132e135,137
N¼ 745
n¼ 6
n $50%¼ 1
30e9 138,139,
142 45,c
N¼ 1 25
n¼ 6
n $50 ¼ 5
42e85%147,148,
152,154
N¼ 327
n¼ 4
n $50%¼ 2
52e76%152,155,d
N¼ 102
n¼ 2
68%156
N¼ 52
n¼ 1
Nausea-vomiting
n¼ 67
2e78%5,16e25,27e35,
40e50,52,54,56e60,
63,65,67e71
N¼ 31,743
n¼ 48
n $50%¼ 3
4%79
N¼ 81
n¼ 1
2e48%79,81,
83,84
N¼ 812
n¼ 4
8e52%86,87,90,
91,101,103,
106,117,128,b
N¼ 1176
n¼ 9
n $50%¼ 1
8%137
N¼ 50
n¼ 1
41e5 138,139,
143 5,c
N¼ 9 4
n¼ 4
n $50 ¼ 1
- - 26%156
N¼ 52
n¼ 1
Breathlessness/
dyspnea/
shortness of
breath/respiratory
distress
n¼ 73
16e77%5,16e21,23e35,
37e54,56e60,63,65,
67e71
N¼ 33,175
n¼ 40
n $50%¼ 16
56e98%1,72e75,
77,79,80,a
N¼ 1835
n¼ 8
18e88%73,79,
81e85
N¼ 1230
n¼ 7
n $50%¼ 5
11e82%86e88,90
,91,93,95,100,
101,117,131,b
N¼ 1031
n¼ 11
n $50%¼ 4
12e52%85,
132e134,137
N¼ 674
n¼ 5
n $50%¼ 1
43e6 138,
139 5,c
N¼ 8 1
n¼ 3
n $50 ¼ 3
- 81e88%155,d
N¼ 52
n¼ 1
26%156
N¼ 52
n¼ 1
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Insomnia/
poor sleeping/
difficulty
sleeping/
sleep
disturbance
n¼ 65
3e67%5,16e18,20,21,
23e25,27,29,31,32,34,
35,37,38,41,
43,45,47e50,
52,56e59,
63,65,67,70
N¼ 21,725
n¼ 33
n $50%¼ 11
15e77%1,74,75,77,a
N¼ 419
n¼ 4
n $50%¼ 3
36e48%81,83,84
N¼ 746
n¼ 3
1e83%87,88,91,93,
98,101,103,
117e120,
122e127,131
N¼ 2265
n¼ 18
n $50%¼ 7
14%136
N¼ 123
n¼ 1
40e74%138,139,
145,c
N¼ 811
n¼ 3
n $50%¼ 3
43e50%149,154
N¼ 224
n¼ 2
n $50%¼ 1
24e33%155,d
N¼ 52
n¼ 1
-
Confusion/
delirium/
cognitive
failure/
cognitive
symptoms
n¼ 31
2e68%18,22,23,27,
29,31e34,
38,40,41,44,
46e52,56,
57,62,65,71
N¼ 18,768
n¼ 25
n $50%¼ 3
14e33%1,73,a
N¼ 309
n¼ 2
15e48%73,82,83
N¼ 433
n¼ 3
35e70%86,b
N¼ 32
n¼ 1
- - 24%154
N¼ 123
n¼ 1
- -
Constipation
n¼ 60
4e64%5,18e25,29,30,
32e38,40e50,52,54,
56e60,63,65,
67,69e71
N¼ 30,841
n¼ 42
n $50%¼ 10
12e44%1,75,a
N¼ 150
n¼ 2
12e42%81,83,84
N¼ 746
n¼ 3
8e65%87,88,92,
101,106,130,131
N¼ 1136
n¼ 7
n $50%¼ 3
40%137
N¼ 50
n¼ 1
19e35%138,139,c
N¼ 759
n¼ 2
24%153
N¼ 123
n¼ 1
52e56%155,d
N¼ 52
n¼ 1
46%156
N¼ 52
n¼ 1
Diarrhea
n¼ 33
1e25%5,20,21,23e25,27,
29,32,34,37,40e42,44,
46e48,56e60,69
N¼ 17,813
n¼ 24
- 12%83,84
N¼ 146
n¼ 2
8e36%86e88,131,b
N¼ 105
n¼ 4
- 29e53%138,139,143,c
N¼ 862
n¼ 3
n $50%¼ 2
- - -
Psychological: Depression/
depressive
mood/sadness/
low mood
n¼ 71
4e80%5,16,
18e20,23,
27e29,32,
34,37,38,
41,47,48,50,
52,56,57,63,
65,68e71
N¼ 16,200
n¼ 26
n $50%¼ 10
17e77%1,74,76e80,a
N¼ 752
n¼ 7
n $50%¼ 4
6e59%79e81,83,84
N¼ 892
n¼ 5
n $50%¼ 1
2e61%87e89,91,
96e100,102,
104e116
N¼ 7644
n¼ 23
n $50%¼ 3
46%136
N¼ 123
n¼ 1
17e82%138e140,142,
143,145
N¼ 1211
n¼ 6
n $50%¼ 4
15e50%146,
149e151,153
N¼ 24,759
n¼ 5
n $50%¼ 1
23%153
N¼ 119
n¼ 1
15%153
N¼ 162
n¼ 1
Anxiety/
nervousness/
agitation
n¼ 50
3e74%5,16,20,28,32,38,
47,48,50,52,56,57,63,
65,66,68e71
N¼ 14,724
n¼ 19
n $50%¼ 7
23e53%74,77,79,80
N¼ 455
n¼ 4
n $50%¼ 1
2e49%79e81,83,84
N¼ 892
n¼ 5
7e52%86e88,91,
96,99,100,
106,107,109,b
N¼ 818
n¼ 10
n $50%¼ 1
8e72%133e137
N¼ 708
n¼ 5
n $50%¼ 2
13e76%138e140,145
N¼ 923
n¼ 4
n $50%¼ 2
5e62%146,149,
151,153,154
N¼ 24,842
n¼ 5
n $50%¼ 2
19%153
N¼ 119
n¼ 1
24%153
N¼ 162
n¼ 1
Worry
n¼ 12
3e71%16,23,
27,29,32,57,69
N¼ 1500
n¼ 8
n $50%¼ 3
65%77
N¼ 60
n¼ 1
- 32e55%87,88
N¼ 30
n¼ 2
n $50%¼ 1
- 51e86%138,139,c
N¼ 759
n¼ 2
- - -
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Table 2
Continued
Domain
Problems and
Number of
Different
Studies
for Each
Problem
for All
Diagnostic
Groups (n)
Minimum-Maximum Prevalence % of Each ProblemReferences
Total Sample of Patients (N ) for Each Problem
Total Number of Studies (n) for Each Problem
Number of Studies That Report Prevalence for a Problem as $50% (n $50%)
Cancer COPD CHF ESRD Dementia AIDS Parkinson MND MS
Spiritual: Well-being
n¼ 2
91%70
N¼ 406
n¼ 1
14%79
N¼ 81
n¼ 1
5%79
N¼ 66
n¼ 1
- - - - - -
Spiritual pain
n¼ 1
44%61
N¼ 91
n¼ 1
- - - - - - - -
Spiritual wellbeing
n¼ 1
- - 6%84
N¼ 66
n¼ 1
- - - - - -
Peace
n¼ 0
- - - - - - - - -
Social: Support
n¼ 1
49%71
N¼ 4035
n¼ 1
- - - - - - - -
Information
n¼ 0
- - - - - - - - -
Psychosocial distress
n¼ 0
- - - - - - - - -
COPD¼ chronic obstructive pulmonary disease; CHF¼ chronic heart failure; ESRD¼ end-stage renal disease; AIDS¼ acquired immune deficiency syndrome; MND¼motor neuron disease; MS¼multiple
sclerosis.
A dash indicates that no data were found for this specific problem in this specific diagnostic group.
aThis study included a period prevalence measurement on two time points: in the final year of life and in the final week of life.
bThis study included a point and a period prevalence measurement in the same sample of patients.
cThis study took place in three different sites and contains data for three different samples of patients.
dThis study contains the data of two groups of patients: one group who died at home and one group who died in a hospice.
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Additional records identified 
through other sources
(n = 45)
Records after duplicates removed
(n = 4,697)
Records (abstracts)
screened
(n = 4,670)
Records excluded
(n = 3,597)
Full-text articles 
assessed for eligibility
(n = 241)
Full-text articles 
excluded, with reasons
(n = 98):
-articles presenting
results from effect 
studies;
-articles presenting 
results of studies in 
which the patients were 
in the early stage of 
their life-threatening 
disease;
-articles presenting 
results of validation 
studies of a symptom 
measurement tool;
-articles presenting 
evaluation reports of 
treatment strategies of 
symptoms.
Studies included in 
quantitative synthesis 
(n = 143)
Fig. 2. PRISMA flow diagram of search process.
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tual,61,70,79,84 and one study on social palliative
careerelated71 problems. In people living with
advanced cancer, lack of well-being and sup-
port were the problems that were considerably
prevalent (91% and 49%, respectively).
The problems for which we found the widest
minimum (<10%) and maximum ($50%)
prevalence ranges were: nausea-vomiting in
advanced cancer and ESRD; insomnia in ad-
vanced cancer and ESRD; delirium in advanced
cancer; constipation in advanced cancer andESRD; depression in advanced cancer, CHF
and ESRD; anxiety in advanced cancer, ESRD,
dementia, and Parkinson’s disease; and worry
in advanced cancer.
Looking atmost studies that presented a prev-
alence of 50% andmore in comparison with the
total number of studies for each problem per
diagnostic group, the following problems
showed a prevalence of 50% or higher: fatigue
in advanced cancer, COPD, CHF, ESRD, AIDS,
and MS; anorexia in advanced cancer, COPD,
ESRD, and AIDS; pain in advanced cancer,
670 Vol. 48 No. 4 October 2014Moens et al.COPD, ESRD, AIDS, Parkinson’s disease, MND,
and MS; dyspnea in COPD, CHF, ESRD, AIDS,
andMND; insomnia inCOPD,AIDS, andParkin-
son’s disease; constipation in ESRD and MND;
diarrhea in AIDS; depression in COPD and
AIDS; anxiety in AIDS and Parkinson’s disease;
worry in advanced cancer, COPD, ESRD, and
AIDS; and lack of well-being in advanced cancer.
Within the group of 143 articles, there were
only five studies that directly compared the
prevalence of palliative careerelated problems
with another diagnostic group while using the
same measurement tool.73,79,80,152,153 In these
five studies, COPD patients were compared
with CHF and dementia patients,73,79,80 and
Parkinson’s disease patients to MND and MS
patients.152,153 In these studies, the range of
the minimum and maximum prevalence ranges
was not wide.Discussion
This study showed that there are commonal-
ities in problem prevalence across diagnostic
groups. Some problems were rarely studied,
for example, social and spiritual problems;
and for certain diagnostic groups, we found a
very limited number of problem prevalence
studies, for example, for people living with
MND and MS.
There are a balanced number of strengths,
weaknesses, or limitations in this systematic re-
view. One of the limitations of our study is that
each disease group we selected has its specific
pathology process with its specific (other)
symptoms occurring throughout the trajectory.
For example, muscle cramps, dry skin, muscle
soreness, headaches, and restless legs are spe-
cific for people living with ESRD, but these
are not included in this review as we aimed
to summarize the generally prevalent prob-
lems across all our studied diagnostic groups.
We also recognize publication bias while look-
ing at certain domains of interest; for example,
social and spiritual problems may receive
lower priority from peer-reviewed publications.
Hence, problems for which we could not find
(sufficient) evidence does not mean that these
problems are not present. Another limitation
is that systematic reviews rely on a broad yet ac-
curate search strategy to identify relevant evi-
dence. We tried to limit this by implementinga search strategy using synonyms for specific
palliative careerelated problems. Lastly, from
the beginning of our study, we were aware
that by collecting data on our research topic,
we had to deal with presenting a hetero-
geneous amount of information. This, for
example, resulted in our presenting the data
in a very descriptive way using minimum and
maximum prevalence ranges.
We believe that this review has the following
strengths: using the PRISMA 2009 flowchart to
execute our search in a stepwise way, giving us
a structured overview of which studies were
correctly excluded; assessing the quality of
the review using the PRISMA 2009 checklist
and the AMSTAR measurement tool; reviewing
the evidence on palliative careerelated prob-
lems not only focusing on the physical and psy-
chological problems but also using a total care
view and including prevalence studies of spiri-
tual and social palliative careerelated prob-
lems; using several search or keywords to
describe the same single problem; and
excluding intervention studies to prevent se-
lection bias. We expanded the variety of pallia-
tive careerelated problems and non-cancer
conditions in comparison with the review of
Solano et al,7 allowing us to provide a broader
view on the palliative careerelated problems in
palliative care patients in accord with the
WHO definition of palliative care.8
One of the study’s objectives was to review
the prevalence studies across all palliative
care domains, but only two studies investigated
well-being,70,79 one study the presence of spir-
itual pain,61 one study the lack of spiritual well-
being,84 and one study the problems with
receiving support.71 We can understand this
situation given the current availability and
accessibility of spiritual outcome measurement
tools. There are only nine spiritual outcome
measurement tools that have been validated
in cross-cultural palliative care populations.157
The variations in the minimum and
maximum prevalence ranges were likely
caused by the differences in time points of
data collection (point vs. period prevalence,
or a mix of both), the period prevalence
time ranges, the varying definitions for a prob-
lem, the sample size proportions, and the
various different measurement methods used
across studies. In light of the wide variations
in the minimum and maximum prevalence
Vol. 48 No. 4 October 2014 671Prevalence of Palliative Care Problemsranges and the methodological heterogeneity
across studies, and the insights gained by look-
ing at the five direct comparison studies, we
can state that there is as much variation in
prevalence between diagnostic groups as there
is similarity. Also, understanding the preva-
lence of palliative careerelated problems of
non-cancer patients in comparison with cancer
patients is complex as a result of the varying
trajectories of functional decline and depen-
dency in non-cancer diagnostic groups,158
and their comorbidities and changing disease
stages. Therefore, although there are com-
monalities in prevalence across diagnostic
groups, the methodological heterogeneity
across studies and the limited number of
non-cancer studies must be taken into consid-
eration when interpreting our results.
Our review identified some gaps that need
to be addressed in future research. More
research is needed that directly compares palli-
ative careerelated problems between cancer
and non-cancer patients using the same mea-
surement tools and time points. Our results
also call for an intensification of the measure-
ment and reporting of spiritual and social
palliative careerelated problems.
We also found that pain, fatigue, anorexia,
dyspnea, and anxiety were highly prevalent
problems across advanced cancer and non-
cancer diagnostic groups. Health care providers
should be aware of these problems and be more
sensitive to their assessment and treatment.
Future prevalence studies should build on the
findings of our review in terms of the most often
used measurement methods across studies, and
our identified evidence gaps, particularly in the
under-researched non-cancer patient groups.
In conclusion, our study reveals that there is
as much variation within diagnostic groups as
between groups in relation to prevalence of
palliative careerelated problems. Our study
can be considered as an epidemiological needs
assessment while using the summarized preva-
lence data of palliative careerelated problems
among advanced cancer and non-cancer pa-
tients indicating that both are in need of pa-
lliative care. These summarized prevalence
figures across diagnostic groups support the
conclusion that palliative care should be
made available based on the problems and
needs patients exhibit, and not based on the
diagnostic group to which a patient belongs.Disclosures and Acknowledgments
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